As of today (2024-06-14), Thoratec's share price is €55.92.
Thoratec's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2015 was €1.54. Hence, Thoratec's Price-to-Free-Cash-Flow Ratio for today is 36.22.
The historical rank and industry rank for Thoratec's Price-to-Free-Cash-Flow or its related term are showing as below:
FRA:TL1'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.7 Med: 27.25 Max: 2321.11
Current: 35.22
During the past 13 years, Thoratec's highest Price-to-Free-Cash-Flow Ratio was 2321.11. The lowest was 12.70. And the median was 27.25.
FRA:TL1's Price-to-Free-Cash-Flow is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 32.86
vs FRA:TL1: 35.22
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Thoratec was -1.60% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.60% per year.
During the past 13 years, Thoratec's highest 3-Year average Free Cash Flow per Share Growth Rate was 102.00% per year. The lowest was -25.20% per year. And the median was 21.70% per year.
Thoratec Price-to-Free-Cash-Flow Historical Data
The historical data trend for Thoratec's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Thoratec's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, Thoratec's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thoratec's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Thoratec's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Thoratec's Price-to-Free-Cash-Flow falls into.
Thoratec Price-to-Free-Cash-Flow Calculation
Thoratec's Price-to-Free-Cash-Flow ratio for today is calculated as
Thoratec's Share Price of today is €55.92. Thoratec's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thoratec Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Thoratec's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TL1 has been successfully added to your 